Crk II (phospho Tyr221) Rabbit Polyclonal Antibody($99/20μL)

Crk II (phospho Tyr221) Rabbit Polyclonal Antibody($99/20μL)

Size1:20μL Price1:$99
Size2:50μL Price1:$128
Size3:100μL Price2:$230
Size4:200μL Price3:$380
Application:WB,IF-P,IF-F,ICC/IF,ELISA

Reactivity:Human,Mouse,Rat,Monkey
Conjugate:Unconjugated
Optional conjugates: Biotin, FITC (free of charge).
See other 26 conjugates.

Gene Name:CRK
SKU: APRab04500 Category: Polyclonal Antibody Tags: , , , , , , , , ,

Summary

Production Name

Crk II (phospho Tyr221) Rabbit Polyclonal Antibody

Description

Rabbit Polyclonal Antibody

Host

Rabbit

Application

WB,IF-P,IF-F,ICC/IF,ELISA

Reactivity

Human,Mouse,Rat,Monkey

 

Performance

Conjugation

Unconjugated

Modification

Phospho Antibody

Isotype

IgG

Clonality

Polyclonal

Form

Liquid

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Buffer

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.

Purification

Affinity purification

 

Immunogen

Gene Name

CRK

Alternative Names

CRK; Adapter molecule crk; Proto-oncogene c-Crk; p38

Gene ID

1398

SwissProt ID

P46108

 

Application

Dilution Ratio

WB 1:500-1:2000, IF-P/IF-F/ICC/IF 1:200-1:1000, ELISA 1:40000.Not yet tested in other applications.

Molecular Weight

40kDa

 

Background

This gene encodes a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. The product of this gene has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation. Two alternative transcripts encoding different isoforms with distinct biological activity have been described. [provided by RefSeq, Jul 2008],domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation.,domain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4.,PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the down-regulation of the Crk signaling pathway.,PTM:Phosphorylation of Crk-II (40 kDa) gives rise to a 42 kDa form.,similarity:Contains 1 SH2 domain.,similarity:Contains 1 SH3 domain.,similarity:Contains 2 SH3 domains.,subcellular location:Translocated to the plasma membrane upon cell adhesion.,subunit:Interacts with ABL1, C3G, SOS, MAP4K1, MAPK8 and DOCK3 via its first SH3 domain. Interacts with BCAR1, CBL, CBLB, PXN, IRS4 and GAB1 via its SH2 domain upon stimulus-induced tyrosine phosphorylation. Interacts with several tyrosine-phosphorylated growth factor receptors such as EGFR, PDGFR and INSR via its SH2 domain (By similarity). Interacts with DOCK1 and DOCK4. Interacts with SHB.,

 

Research Area

MAPK_ERK_Growth;MAPK_G_Protein;ErbB_HER;Chemokine;Focal adhesion;Fc gamma R-mediated phagocytosis;Neurotrophin;Regulates Actin and Cytoskeleton;Insulin_Receptor;Pathways in cancer;Renal cell carcinoma;Chronic myeloid leukemia;